SAN DIEGO, March  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ:PEPG). The investigation focuses on whether PepGen or certain of its

PEPG

PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

FDA Hold on PepGen Trial Triggers Investor Investigation and Stock Decline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, March  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ:PEPG). The investigation focuses on whether PepGen or certain of its</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>PepGen Inc. has faced a partial clinical hold from the FDA on its PGN-EDODM1 trial, raising investor concerns and triggering a notable stock price drop. The situation has led to an investigation by Johnson Fistel into potential securities law violations by the company, revealing heightened regulatory risks and uncertainty around the clinical program.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>FDA placed a partial clinical hold on PepGen&#039;s PGN-EDODM1 trial due to concerns.</li><li>Investors reacted negatively, leading to a significant stock price drop.</li><li>Law firm Johnson Fistel is investigating potential federal securities violations.</li><li>Investors who lost money are encouraged to participate in the investigation.</li><li>Concerns around preclinical data may hinder future clinical trial progress.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>PepGen Inc. (PEPG)</strong>: Facing regulatory scrutiny and potential legal issues affecting stock performance.</li><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Law firm&#039;s investigation may instigate further turmoil for PEPG as scrutiny deepens.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This news falls under &#039;Legal&#039; due to the investigation into compliance with federal securities laws, directly impacting investor confidence and stock valuation. The situation is exacerbated by regulatory concerns from the FDA.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA&#039;s action raises regulatory and operational risks for PepGen.</li><li>Potential securities violations could lead to further legal and financial ramifications.</li><li>Investor confidence likely to wane causing additional stock price pressure.</li><li>Continued scrutiny on clinical trials could lead to more volatility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>FDA placed a partial clinical hold on March 5, 2026.</li><li>The hold affects the FREEDOM2-DM1 Phase 2 trial for PGN-EDODM1.</li><li>PepGen&#039;s stock price sharply declined following the announcement.</li><li>Johnson Fistel is investigating potential federal securities law violations.</li><li>Investors are encouraged to join the investigation if they suffered losses.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should be cautious; consider shorting PEPG amid ongoing regulatory issues over the coming months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, March  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PEPG">PEPG</a>). The investigation focuses on whether PepGen or certain of its executives violated federal securities laws.</p>  <p><strong>What if I purchased PepGen securities?</strong></p>  <p>If you purchased PepGen securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.</p>  <p>Or for more information, contact Jim Baker at <a href="https://www.globenewswire.com/Tracker?data=E9SEdSkf6O6C9g08Yxz_4kf8lbSrQx2k2sFDRq_xl1m55WNGLxgWSC8iE4F77nP_GOJBtLHoMyFjuPWr-3shUY7X5Bj6k6cTm22cJ6RNXww=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p><strong>Background of the investigation</strong></p>  <p>On March 5, 2026, PepGen disclosed that the U.S. Food and Drug Administration ("FDA") had placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1. The Company stated that the clinical hold was imposed due to concerns related to previously submitted preclinical pharmacology and toxicology studies.</p>  <p>Following this announcement, PepGen's stock price declined sharply during intraday trading on March 5, 2026, as investors reacted to the regulatory development and the uncertainty surrounding the FREEDOM2 clinical program.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether PepGen complied with the federal securities laws. If you suffered losses from your investment in PepGen stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong></p>  <p>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=QEczCMbeZCfbx1VbRBucjZ_LdSQy7BfvRcV-zInklJhKXHXEWhNwZGl3_23jQVUoC8GTCfOdGaGRRjU0Pi6neRy6m8ZQb9-tB1mWpZP5nUY=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong></p>  <p>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm's effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs' securities law firm in the United States, based on the total dollar value of final recoveries.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NzE1MiM3NDcxMzAyIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NDJiNjZkZTYtZTNhZS00MDZiLWE4ZjYtMjgzZjc5NzFiYzcyLTExOTMzNTgtMjAyNi0wMy0wNi1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

PepGen Inc. has faced a partial clinical hold from the FDA on its PGN-EDODM1 trial, raising investor concerns and triggering a notable stock price drop. The situation has led to an investigation by Johnson Fistel into potential securities law violations by the company, revealing heightened regulatory risks and uncertainty around the clinical program.

PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News